Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Mol Cell Biol ; 27(14): 5147-60, 2007 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-17515611

RESUMO

Tumor necrosis factor alpha (TNF-alpha) is a potent cytokine which regulates inflammation via the induction of adhesion molecules and chemokine expression. Its expression is known to be regulated in a complex manner with transcription, message turnover, message splicing, translation, and protein cleavage from the cell surface all being independently regulated. This study examined both cell lines and primary cells to understand the developmental regulation of epigenetic changes at the TNF-alpha locus. We demonstrate that epigenetic modifications of the TNF-alpha locus occur both developmentally and in response to acute stimulation and, importantly, that they actively regulate expression. DNA demethylates early in development, beginning with the hematopoietic stem cell. The TNF-alpha locus migrates from heterochromatin to euchromatin in a progressive fashion, reaching euchromatin slightly later in differentiation. Finally, histone modifications characteristic of a transcriptionally competent gene occur with myeloid differentiation and progress with differentiation. Additional histone modifications characteristic of active gene expression are acquired with stimulation. In each case, manipulation of these epigenetic variables altered the ability of the cell to express TNF-alpha. These studies demonstrate the importance of epigenetic regulation in the control of TNF-alpha expression. These findings may have relevance for inflammatory disorders in which TNF-alpha is overproduced.


Assuntos
Epigênese Genética , Fator de Necrose Tumoral alfa/genética , Acetilação/efeitos dos fármacos , Adenosina/análogos & derivados , Adenosina/farmacologia , Animais , Diferenciação Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Núcleo Celular/efeitos dos fármacos , Núcleo Celular/metabolismo , Metilação de DNA/efeitos dos fármacos , Células-Tronco Embrionárias/citologia , Células-Tronco Embrionárias/efeitos dos fármacos , Epigênese Genética/efeitos dos fármacos , Eucromatina/metabolismo , Histonas/metabolismo , Humanos , Hibridização in Situ Fluorescente , Camundongos , Modelos Genéticos , Transporte Proteico/efeitos dos fármacos , Sulfitos , Tionucleosídeos/farmacologia
2.
Clin Genet ; 67(4): 335-40, 2005 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15733270

RESUMO

Primary congenital glaucoma (PCG) has been associated with CYP1B1 gene (2p21), with a predominantly autosomal recessive mode of inheritance. Our earlier studies attributed CYP1B1 mutations to only 40% of Indian PCG cases. In this study, we included 72 such PCG cases where CYP1B1 mutations were detected in only 12 patients in heterozygous condition, implying involvement of other gene(s). On screening these patients for mutations in myocilin (MYOC), another glaucoma-associated gene, using denaturing high-performance liquid chromatography followed by sequencing, we identified a patient who was double heterozygous at CYP1B1 (c.1103G>A; Arg368His) and MYOC (c.144G>T; Gln48His) loci, suggesting a digenic mode of inheritance of PCG. In addition, we identified the same MYOC mutation, implicated for primary open angle glaucoma, in three additional PCG patients who did not harbor any mutation in CYP1B1. These observations suggest a possible role of MYOC in PCG, which might be mediated via digenic interaction with CYP1B1 and/or an yet unidentified locus associated with the disease.


Assuntos
Proteínas do Olho/genética , Glaucoma/congênito , Glaucoma/genética , Glicoproteínas/genética , Hidrocarboneto de Aril Hidroxilases/genética , Citocromo P-450 CYP1B1 , Proteínas do Citoesqueleto , Feminino , Haplótipos , Humanos , Masculino , Mutação Puntual
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...